The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
RosenbergJ., CensitsJ., PowlesT.Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single arm, multicenter, phase 2 trial. Lancet Oncol.2016; 387(10031): 1909–1920.
2.
HerbstR., SoriaJ.C., KowanetzM.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature.2014; 515(7528); 563–567.
HerbstR.S., GordonM.S., FineG.D.A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol.2013; 31(suppl): abstract 3000.
5.
DengR., BumbacaD., PastuskovasC.Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MABS.2016; 8(3); 593–603.
6.
McDermottD., SosmanJ., SznolM.Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: Long-term safety, clinical activity, and immune correlates from a phase 1a study. J Clin Oncol.2016; 34(8): 833–841.
7.
PowlesT., EderJ.P., FineG.D.MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature.2014; 515(7528): 558–562.
8.
FehrenbacherL., SpiraA., BallingerM.Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicenter open label, phase 2 randomised controlled trial. Lancet.2016; 387: 1837–1846.
9.
ZhuA., KudoM., AssenatE.Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib the EVOLVE-1 randomized clinical trial. JAMA.2014; 312(1): 57–67.
10.
XuB., WuY., ShenL.Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. J Hematol Oncol.2011; 4(3): 1–7.
11.
WagleN., GrabinerB., Van AllenE.Activating mTOR mutations in a patient with an extraordinatory response on a phase 1 trial of everolimus and pazopanib. Cancer Discov.2014; 4(5): 546–553.
12.
Peveling-OberhagJ., ZeuzemS., YongW.Effect of hepatic impairment on the pharmacokinetics of everolimus: A single-dose, open-label, parallel-group study. Clin Ther.2013; 35(3): 215–225.
MotzerR.J., EscudierB., McDermottD.Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med.2016; 373(19): 1803–1813.
15.
ChoueiriT.K., EscudierB., PowlesT.Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med.2015; 373(19): 1814–1823.
16.
YoaJ., FazioN., SinghS.Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study. Lancet.2016; 387(10022): 968–977.
